Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931944 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Knopp Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 19
- Study locations
NCT00931944 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Knopp Biosciences. The registered enrollment target is 74 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (92% lower). The trial reports 19 study locations across 15 states.
The verdict
NCT00931944, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Knopp Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
Conditions Studied
Interventions
- DRUG KNS-760704
Study Locations (19)
Pennsylvania
- Penn State Hershey Medical Center - Hershey
- Drexel University College Of Medicine - Philadelphia
- University of Pittsburgh School of Medicine - Pittsburgh
California
- UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center - Los Angeles
- The Forbes Norris MDA/ALS Research Center - San Francisco
New York
- Columbia University, Lou Gehrig MDA/ALS Research Center - New York
- SUNY Upstate Medical University - Syracuse
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Florida
- University of Miami Miller School of Medicine - Miami
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Massachusetts
- Massachusettes General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00931944
The ClinicalTrials.gov registry entry for NCT00931944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (92% lower). The listed sponsor is Knopp Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which KNS-760704 is the first listed.
NCT00931944 reports 19 study locations spanning 15 distinct geographic areas - top geographies include Pennsylvania, California, New York.
Frequently Asked Questions
What is clinical trial NCT00931944 about?
NCT00931944 is a clinical study titled "Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)". This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
What is the current status of trial NCT00931944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2009-07. Estimated completion is 2013-07.
What conditions does trial NCT00931944 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT00931944?
The interventions under investigation include: KNS-760704 (DRUG).
Who is sponsoring clinical trial NCT00931944?
This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00931944 being conducted?
This trial has 19 study locations across Arkansas, California, Florida, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.